Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide can cause itching in some people, though it is not among the most commonly reported side effects. Injection-site reactions (including localised redness, itching or mild swelling) are documented in the clinical trial data for Wegovy, and a smaller number of patients report more generalised skin itching. Most reactions are mild and short-lived, but a sudden, widespread itch shortly after a dose deserves prompt medical attention because it can occasionally signal an allergic response. If you are weighing up semaglutide and wondering whether skin reactions are likely to be a problem for you, that is the kind of question a prescriber can work through properly before treatment starts — and our prescribers are available through a free consultation if you would like a clinical view.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most rigorous answer to whether semaglutide causes itching comes from the STEP 1 trial, a 68-week randomised study in adults with obesity, published in the New England Journal of Medicine, which compared semaglutide 2.4 mg against placebo alongside lifestyle changes. Injection-site reactions were among the adverse events logged: they included redness, bruising, pain and localised itching at the point of injection. These reactions were generally mild and transient, appearing most often in the first weeks of treatment while participants were still at lower doses.
The NHS medicines page for semaglutide categorises injection-site reactions as a common side effect (meaning they occur in roughly one in ten to one in a hundred people) and lists localised itching explicitly. Generalised pruritus (itching across a broader area of skin, not confined to the injection site) also appears in post-marketing data, though at lower frequency. The distinction matters: site-specific itching is usually mechanical or inflammatory in origin, whereas generalised itching raises a different set of questions worth discussing with a prescriber.
Semaglutide slows gastric emptying and alters gut-hormone signalling, but the link between those mechanisms and skin reactions is indirect. Injection-site responses are more plausibly immune-mediated or related to the delivery vehicle, and they tend to resolve without any change to treatment. Rotating injection sites (abdomen, thigh, upper arm) is the standard practical step, and the full guidance on technique is set out in the patient information leaflet that comes with every Wegovy pen.
If you notice a small area of redness or itching exactly where the pen was used, and it clears within a day or two, that is consistent with a localised injection-site reaction. Annoying, but not dangerous. The situation changes if itching appears across a wide area of skin, is accompanied by hives, or arrives alongside swelling of the lips, tongue or throat and any sense of breathlessness. Those symptoms together point to a possible allergic reaction, which requires urgent medical help, call 999 or go to A&E; do not wait for your next appointment.
Genuine anaphylaxis from semaglutide is rare, but it has been reported. The MHRA's Yellow Card scheme is the mechanism through which patients and healthcare professionals report suspected reactions like this, and doing so helps regulators build a clearer picture of how often serious skin reactions actually occur in the wider population. If you are unsure whether what you are experiencing is a local irritation or something more systemic, that uncertainty alone is reason enough to contact a healthcare professional rather than waiting it out.
Some people also find that itching flares temporarily after a dose increase. As the dose of semaglutide rises through the titration schedule, the body is recalibrating, and mild skin symptoms sometimes accompany that adjustment period. This is not unusual, and it is worth reading more about the patterns of semaglutide-related itching if you have been dealing with it repeatedly at each new dose level.
If localised injection-site itching is bothering you, there are a few things worth trying before concluding that semaglutide is not right for you. Rotating the injection site every week reduces the chance of cumulative skin irritation in one area. Letting the pen reach room temperature before use (rather than injecting straight from the fridge) is something many patients find helpful. Keeping the skin clean and dry at the injection site matters too, and it is worth checking you are not pressing the pen against the same small patch of skin each time.
If you are also noticing broader skin changes alongside the injection-site reactions, such as dryness or a rash appearing elsewhere, that is worth flagging at your next clinical review rather than managing on your own. Semaglutide is a prescription-only medicine, and ongoing skin symptoms are exactly the kind of thing the prescribing team is there to assess, not something to simply endure.
Persistent or worsening itching should always be discussed with a prescriber. That is not a precaution for edge cases; it is the normal expectation for anyone on a POM. At nume, every repeat order goes through a fresh clinical review (a real prescriber reads your update, not automated software) so if a skin reaction has developed since your last dose, that is the right moment to raise it. You can also reach the team directly via our support line, which is available seven days a week.
Skin reactions are one part of a broader side-effect picture for semaglutide. The most commonly reported effects are gastrointestinal, nausea, changes in bowel habits, and feelings of fullness that can arrive quickly during meals. If you are curious about how digestive symptoms like gas and bloating compare in frequency to skin reactions, the NHS semaglutide page gives a useful ranked breakdown. Less commonly reported effects include fatigue and headaches, particularly around the time of a dose increase.
Some people arrive at their consultation with questions that go well beyond the standard side-effect list, for instance, whether Wegovy can cause eye twitching or other effects that sit outside the most familiar categories. Those are reasonable things to bring up. Our clinical team fields questions like this regularly, and a consultation is genuinely the right format: it is free, there is no obligation, and having a prescriber weigh up your specific health picture is more useful than any general article can be.
If you are still in the research stage, the Wegovy overview page covers how semaglutide works, what the licensed indications are, and what private treatment through a regulated UK pharmacy typically involves. For anything more personal, such as whether semaglutide affects sexual function, speaking to our prescribers is the right next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.